SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.

Jones, RJ, Bahl, A, De Bono, JS et al. (17 more authors) (2021) SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group. In: 2021 Genitourinary Cancers Symposium, 11-13 Feb 2021, Online.

Metadata

Authors/Creators:
  • Jones, RJ
  • Bahl, A
  • De Bono, JS
  • Ralph, C ORCID logo https://orcid.org/0000-0001-5581-2987
  • Elliott, T
  • Robinson, A
  • Westbury, C
  • Birtle, AJ
  • Staffurth, JN
  • Protheroe, A
  • Venugopal, B
  • Thomson, F
  • Pou, C
  • Morris, K
  • Tugwood, J
  • Divers, L
  • Hopkins, C
  • McCartney, E
  • Kelly, C
  • Crabb, SJ
Dates:
  • Published: 20 February 2021
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 27 Feb 2023 16:58
Last Modified: 27 Feb 2023 16:58
Status: Published
Identification Number: https://doi.org/10.1200/jco.2021.39.6_suppl.107
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)